iRhythm Holdings, Inc. (IRTC) Stock Analysis
Recovery setup
Healthcare · Medical Devices
Sell if holding. Multiple concerning factors at $113.94: Concentration risk — Product: iRhythm Services; V7 low-quality RISK_OFF penalty: -0.5 (Q=4.0).
iRhythm provides ambulatory cardiac monitoring services using its Zio patch biosensors (up to 14-day continuous wear) and proprietary cloud-based ZEUS analysis software via Medicare-enrolled IDTFs. It is the market leader delivering over 70% of LTCM services in the U.S.; ~24% of... Read more
Sell if holding. Multiple concerning factors at $113.94: Concentration risk — Product: iRhythm Services; V7 low-quality RISK_OFF penalty: -0.5 (Q=4.0). Chart setup: Death cross but MACD improving, RSI 45. Score 5.9/10, moderate confidence.
Passes 7/9 gates (positive momentum, favorable risk/reward ratio, clean insider activity, news boost analyst 0.60, earnings proximity 50d clear, semi cycle peak clear, materials cycle peak clear). Fails on SEC filing concern. Suitability: aggressive.
Recent developments
updated 2026-06-11Recent Developments — iRhythm Holdings, Inc.
Latest news
- NEWS Here's why you should retain IRTC stock in your portfolio for now - MSN — MSN positive
- NEWS IRTC (iRhythm Holdings Inc.) delivers massive Q4 2025 EPS beat against analyst estimates, stock rises modestly in daily — Cổng thông tin điện tử tỉnh Tây Ninh positive
- NEWS IRTC Reiterated by BTIG -- Price Target Maintained at $185 - GuruFocus — GuruFocus positive
- NEWS Is It Time To Reassess iRhythm Holdings (IRTC) After Recent Share Price Rebound - Yahoo Finance — Yahoo Finance positive
- NEWS How New Zio Data and iRhythm Academy Could Shape iRhythm Holdings’ (IRTC) Cardiac Care Strategy - Sahm — Sahm positive
Generated 2026-06-15T18:11:46Z.
Upcoming dated catalysts
Thesis
Key Metrics
Quality Signals
Options Flow
Concentration Risks(10-K Item 1A)
- HIGHProductiRhythm Services10-K Item 1A: 'Our current revenue is dependent on orders for our iRhythm Services, and we expect that reimbursement for our iRhythm Services will account for substantially all our revenue for the foreseeable future.'
- LOWregulatoryMedicare program (CMS)24%10-K Item 1A: 'During the year ended December 31, 2025, we received approximately 24% of our total revenue from the Medicare program through CMS.'
Material Events(8-K, last 90d)
- 2026-04-01Item 4.01HIGHPricewaterhouseCoopers LLP dismissed as independent registered public accounting firm on March 30, 2026. No disagreements or reportable events in PwC audit reports for FY2025 and FY2024. Successor auditor not named in this filing.SEC filing →
- 2026-03-12Item 5.02LOWJason Patten appointed as director and Audit Committee member effective March 12, 2026, for term expiring at 2026 Annual Meeting. Board determined Patten is independent under Nasdaq standards.SEC filing →
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Rating Breakdown
2 floor-breakers·1 ceiling hit
Technicals below the gate floor. Component breakdown shows what dragged the score down.static
Ranks in the bottom of its industry peers on the composite signal. Better names in the same sector exist.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Sell if holding. Multiple concerning factors at $113.94: Concentration risk — Product: iRhythm Services; V7 low-quality RISK_OFF penalty: -0.5 (Q=4.0). Chart setup: Death cross but MACD improving, RSI 45. Prior stop was $105.96. Score 5.9/10, moderate confidence.
Take-profit target: $155.67 (+36.6% upside). Prior stop was $105.96. Stop-loss: $105.96.
Concentration risk — Product: iRhythm Services; V7 low-quality RISK_OFF penalty: -0.5 (Q=4.0); Leverage penalty (D/E 4.5): -1.5.
iRhythm Holdings, Inc. trades at a P/E of N/A (forward 108.3). TrendMatrix value score: 6.8/10. Verdict: Sell.
21 analysts cover IRTC with a consensus score of 4.3/5. Average price target: $179.
What does iRhythm Holdings, Inc. do?iRhythm provides ambulatory cardiac monitoring services using its Zio patch biosensors (up to 14-day continuous wear)...
iRhythm provides ambulatory cardiac monitoring services using its Zio patch biosensors (up to 14-day continuous wear) and proprietary cloud-based ZEUS analysis software via Medicare-enrolled IDTFs. It is the market leader delivering over 70% of LTCM services in the U.S.; ~24% of 2025 revenue came from Medicare.